ELAB
Elevai Labs, Inc. Common Stock
NASDAQ: ELAB · HEALTHCARE · BIOTECHNOLOGY
$2.53
-0.39% today
Updated 2026-04-29
Market cap
$11.08M
P/E ratio
—
P/S ratio
18.78x
EPS (TTM)
$-382.61
Dividend yield
—
52W range
$2 – $269
Volume
9.0M
Elevai Labs, Inc. Common Stock (ELAB) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-217164.00 | $-660934.00 | $-1.59M | $-4.56M | $-5.49M | $-5.93M |
| Capital expenditures | $0.00 | $32482.00 | $35527.00 | $11191.00 | $9160.00 | $448255.00 |
| Depreciation | — | $2757.00 | $6512.00 | $11649.00 | $12950.00 | — |
| Stock-based comp | — | $142355.00 | $171869.00 | $487738.00 | $97167.00 | $-19160.00 |
| Free cash flow | $-217164.00 | $-693416.00 | $-1.62M | $-4.57M | $-5.50M | $-6.38M |
| Investing cash flow | — | $-32482.00 | $-32027.00 | $-11191.00 | $-610564.00 | — |
| Financing cash flow | $238284.00 | $1.09M | $2.36M | $6.74M | $6.76M | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |